Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma

Status Completed

Clinical Trial Summary

The aim is to study the effect of OC000459 on eosinophilic airway inflammation and asthma control in subjects with severe, refractory eosinophilic asthma.

Clinical Trial Description

At week 12 subjects not on oral corticosteroids (OCS) will complete the treatment period and return after 4 weeks for final follow up visit. Those subjects who were taking OCS at baseline will continue for a maximum of 12 additional weeks, double blind period during which their current OCS treatment will be titrated down according to their clinical response. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02560610
Study type	Interventional
Source	Chiesi Farmaceutici S.p.A.
Contact
Status	Completed
Phase	Phase 2
Start date	September 2016
Completion date	August 2, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04680611` - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting	`NCT06069310` - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Not yet recruiting	`NCT03652376` - Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma	Phase 4
Recruiting	`NCT04542902` - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma	N/A
Completed	`NCT05180357` - RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
Active, not recruiting	`NCT03833141` - Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
Completed	`NCT05271526` - Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Not yet recruiting	`NCT06302959` - Clock Proteins as Prognostic Markers
Recruiting	`NCT05440656` - A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
Completed	`NCT04159519` - A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab	Phase 4
Completed	`NCT03907137` - Real World Study With Benralizumab in Severe Asthma in Switzerland
Active, not recruiting	`NCT04084613` - Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
Completed	`NCT04126499` - Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Recruiting	`NCT03739320` - A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma